​

Karyopharm Therapeutics (KPTI) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Karyopharm Therapeutics Revenue Highlights

Latest Revenue (Y)

$145.24M

Latest Revenue (Q)

$37.93M

Main Segment (Y)

License and Service

Main Geography (Y)

CANADA

Karyopharm Therapeutics Revenue by Period

Karyopharm Therapeutics Revenue by Year

DateRevenueChange
2024-12-31$145.24M-0.55%
2023-12-31$146.03M-7.03%
2022-12-31$157.07M-25.14%
2021-12-31$209.82M94.12%
2020-12-31$108.08M164.31%
2019-12-31$40.89M34.80%
2018-12-31$30.34M1790.09%
2017-12-31$1.60M942.21%
2016-12-31$154.00K-38.40%
2015-12-31$250.00K9.17%
2014-12-31$229.00K-40.83%
2013-12-31$387.00K-38.96%
2012-12-31$634.00K317.11%
2011-12-31$152.00K-

Karyopharm Therapeutics generated $145.24M in revenue during NA 2024, up -0.55% compared to the previous quarter, and up 355.16% compared to the same period a year ago.

Karyopharm Therapeutics Revenue by Quarter

DateRevenueChange
2025-06-30$37.93M26.37%
2025-03-31$30.02M-1.73%
2024-12-31$30.54M-21.25%
2024-09-30$38.78M-9.36%
2024-06-30$42.79M29.16%
2024-03-31$33.13M-1.84%
2023-12-31$33.75M-6.28%
2023-09-30$36.01M-4.18%
2023-06-30$37.58M-2.89%
2023-03-31$38.70M15.24%
2022-12-31$33.58M-7.10%
2022-09-30$36.15M-8.91%
2022-06-30$39.68M-16.76%
2022-03-31$47.67M-62.25%
2021-12-31$126.27M235.03%
2021-09-30$37.69M66.76%
2021-06-30$22.60M-2.83%
2021-03-31$23.26M-33.73%
2020-12-31$35.10M64.53%
2020-09-30$21.33M-36.35%
2020-06-30$33.51M84.77%
2020-03-31$18.14M0.23%
2019-12-31$18.10M37.62%
2019-09-30$13.15M38.51%
2019-06-30$9.49M6024.52%
2019-03-31$155.00K-24.76%
2018-12-31$206.00K-13.81%
2018-09-30$239.00K-98.80%
2018-06-30$19.89M98.91%
2018-03-31$10.00M551.89%
2017-12-31$1.53M100.00%
2017-09-30--100.00%
2017-06-30$3.00K-95.59%
2017-03-31$68.00K44.68%
2016-12-31$47.00K-2.08%
2016-09-30$48.00K-18.64%
2016-06-30$59.00K100.00%
2016-03-31--100.00%
2015-12-31$25.00K-66.67%
2015-09-30$75.00K-50.00%
2015-06-30$150.00K100.00%
2015-03-31--100.00%
2014-12-31$15.00K-28.57%
2014-09-30$21.00K-
2014-06-30$21.00K-87.72%
2014-03-31$171.00K714.29%
2013-12-31$21.00K100.00%
2013-09-30--100.00%
2013-06-30$133.00K-42.92%
2013-03-31$233.00K606.06%
2012-12-31$33.00K-2.94%
2012-09-30$34.00K-

Karyopharm Therapeutics generated $37.93M in revenue during Q2 2025, up 26.37% compared to the previous quarter, and up 114.50% compared to the same period a year ago.

Karyopharm Therapeutics Revenue Breakdown

Karyopharm Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24Dec 23Dec 22Dec 21Dec 20
License and Service$28.01M$24.36M$15.67M--
Health Care, Other$2.74M----
License-$3.50M---
Royalty-$1.50M$300.00K--
Product---$98.44M$76.21M
License And Other---$111.38M$31.88M

Karyopharm Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: License and Service (91.10%), and Health Care, Other (8.90%).

Quarterly Revenue by Product

Product/ServiceJun 25Mar 25Dec 24Sep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20
License and Service$7.62M$8.20M$12.86M$8.75M$6.41M$4.45M$5.56M$5.61M$8.74M$437.00K$1.62M$6.53M--------
Other Royalty$100.00K$500.00K$400.00K-----------------
Royalty$1.00M-$1.50M$400.00K$200.00K$1.00M$1.40M$1.00M------------
Health Care, Other-$113.00K$2.29M$241.00K$203.00K---------------
Product------------$28.30M$29.80M$26.72M$20.18M$21.73M$20.22M$21.33M$18.60M
License And Other------------$19.37M$96.47M$10.97M$2.42M$1.53M$14.88M$3.00K$14.91M

Karyopharm Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: License and Service (87.39%), Royalty (11.47%), and Other Royalty (1.15%).

Karyopharm Therapeutics Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 20
CANADA$5.00M

Karyopharm Therapeutics's latest annual revenue breakdown by geography, as of Dec 20: CANADA (100.00%).

Karyopharm Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
KPTIKaryopharm Therapeutics$145.24M$37.93M
MRSNMersana Therapeutics$40.50M$3.06M
FGENFibroGen$29.62M$1.35M
CELUCelularity$22.77M$18.13M
BTAIBioXcel Therapeutics$2.27M$120.00K
EVAXEvaxion Biotech$73.11K$50.88K
INMBINmune Bio$14.00K$50.00K
BCABBioAtla--
SNTISenti Biosciences--
TPSTTempest Therapeutics--

KPTI Revenue FAQ

What is Karyopharm Therapeutics’s yearly revenue?

Karyopharm Therapeutics's yearly revenue for 2024 was $145.24M, representing a decrease of -0.55% compared to 2023. The company's yearly revenue for 2023 was $146.03M, representing a decrease of -7.03% compared to 2022. KPTI's yearly revenue for 2022 was $157.07M, representing a decrease of -25.14% compared to 2021.

What is Karyopharm Therapeutics’s quarterly revenue?

Karyopharm Therapeutics's quarterly revenue for Q2 2025 was $37.93M, a 26.37% increase from the previous quarter (Q1 2025), and a -11.35% decrease year-over-year (Q2 2024). The company's quarterly revenue for Q1 2025 was $30.02M, a -1.73% decrease from the previous quarter (Q4 2024), and a -9.39% decrease year-over-year (Q1 2024). KPTI's quarterly revenue for Q4 2024 was $30.54M, a -21.25% decrease from the previous quarter (Q3 2024), and a -9.50% decrease year-over-year (Q4 2023).

What is Karyopharm Therapeutics’s revenue growth rate?

Karyopharm Therapeutics's revenue growth rate for the last 3 years (2022-2024) was -7.54%, and for the last 5 years (2020-2024) was 34.37%.

What are Karyopharm Therapeutics’s revenue streams?

Karyopharm Therapeutics's revenue streams in c 24 are License and Service, and Health Care, Other. License and Service generated $28.01M in revenue, accounting 91.10% of the company's total revenue, up 15.00% year-over-year. Health Care, Other generated $2.74M in revenue, accounting 8.90% of the company's total revenue

What is Karyopharm Therapeutics’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Karyopharm Therapeutics was License and Service. This segment made a revenue of $28.01M, representing 91.10% of the company's total revenue.